Table III.
Factors influencing outcomes after auto-HCT among high-risk MM patients on univariate analysis.
| Factor | n (%) | Median PFS, (months) | p-value | Median OS (months) | p-value |
|---|---|---|---|---|---|
| Number of high-risk Abnormalities | |||||
| 1 | 30 (42) | 17.73 | 0.001 | 67.07 | 0.003 |
| >1 | 44 (58) | 7.67 | 19.13 | ||
|
| |||||
| Induction with bortezomib | |||||
| Yes | 53 (72) | 10.07 | 0.217 | 22.9 | 0.518 |
| No | 21 (28) | 15.4 | 37.73 | ||
|
| |||||
| Response before auto-HCT | |||||
| ≥PR | 56 (76) | 12.37 | 0.226 | 37.6 | 0.01 |
| <PR | 17 (23) | 8.23 | 12.87 | ||
|
| |||||
| Age at auto-HCT | |||||
| <65 | 61 (82) | 12.37 | 0.343 | 28.17 | 0.342 |
| >65 | 13 (18) | 9.3 | 13.13 | ||
|
| |||||
| Disease Status at Time of auto-HCT | |||||
| First remission | 48 (65) | 12.43 | 0.064 | 51.43 | 0.004 |
| Relapsed/refractory | 25 (34) | 9.3 | 13.13 | ||
|
| |||||
| Bone marrow plasma cell percentage before auto-HCT | |||||
| <10% | 41 (55) | 10.37 | 0.371 | 28.16 | 0.316 |
| >10% | 24 (32) | 8.23 | 14.67 | ||
|
| |||||
| Response to auto-HCT | |||||
| ≥VGPR | 29 (39) | 29 | 0.001 | 67.07 | <0.001 |
| <VGPR | 45 (61) | 7.67 | 14.67 | ||
|
| |||||
| Maintenance therapy after auto-HCT | |||||
| Yes | 15 (20) | 17.67 | 0.364 | 51.43 | 0.121 |
| No | 59 (80) | 9.8 | 19.7 | ||